300573 Shenyang Xingqi Pharmaceutical
- 258.81
- -0.77-0.30%
Shenyang Xingqi Pharmaceutical News
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Express News | Sinqi Pharmaceutical: After 0.01% atropine sulfate eye drops were approved, the production line was uninterrupted for 24 hours
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%
Shenyang Xingqi Pharmaceutical's (SHE:300573) attributable profit rose 80% to 34.7 million yuan in the first quarter from 19.3 million yuan in the year-ago period, according to a Friday filing with th
Sinqi Pharmaceutical (300573): Performance is in line with expectations, low-concentration atropine is on the market
Revenue and profit increased steadily, and the eye drops business grew strongly. Recently, the company released its annual report for the year 23, and the steady increase in revenue and net profit is in line with expectations. In 2023, the company achieved revenue of 1,468 billion yuan (+17.4 year-on-year)
Express News | Sinqi Pharmaceutical: Net profit increased 79.59% year-on-year in the first quarter
Sinqi Pharmaceutical (300573): The operation is in line with expectations, and atropine will soon drive the company's rapid growth
Incident: The company released its 2023 annual report, achieving operating income of 1,468 billion yuan, a year-on-year increase of 17.4%; net profit to mother of 240 million yuan, an increase of 13.4%; deducted non-net profit of 240 million yuan, an increase of 15 percent year-on-year.
Sinqi Pharmaceutical (300573): Performance is in line with expectations, and the major single product atropine is about to be approved for release
The company released its 2023 annual report. For the whole year, the company achieved revenue of 1.47 billion yuan, +17.4% year-on-year, realized net profit of 240 million yuan, +13.4% year-on-year, and realized net profit of 240 million yuan after deduction of non-return to mother, year-on-year +
Review of the 2023 annual performance report of Sinqi Pharmaceutical (300573): The annual report results are in line with expectations, and the performance of large single products is expected to explode
Incident: On April 18, 2024, the company issued an announcement. In 2023, it achieved operating income of 1,468 billion yuan, an increase of 17.42% over the previous year; achieved net profit of 240 million yuan, an increase of 13.39% over the previous year
SDIC Securities released a research report on April 19 stating that it gave Sinqi Pharmaceutical (300573.SZ) a purchase rating, and the target price was 241.50 yuan. The main reasons for the rating include: 1) continued release of core products to help th
SDIC Securities released a research report on April 19 stating that it gave Sinqi Pharmaceutical (300573.SZ) a purchase rating, and the target price was 241.50 yuan. The main reasons for the rating include: 1) continued release of core products to help the company's performance grow steadily; 2) sales of key varieties of ciclosporin eye drops continued to grow at a high rate after being included in medical insurance. (Mainichi Keizai Shimbun)
Express News | Insurance capital appeared among the top ten tradable shareholders with 32 individual shares
Express News | Sinqi Pharmaceutical: Net profit of 240 million yuan in 2023 increased 13.39% year-on-year, and plans to increase 10 to 4 distributions of 30 yuan
Express News | Guangzheng Ophthalmology: A contract has been signed with Sinqi Pharmaceutical to introduce 0.01% atropine sulfate eye drops
Sinqi Pharmaceutical (300573) Company Review: Low Ah Approves Performance or Embraces Outbreak, Company Continues to Promote “Double Improvement in Quality and Return”
Incident: The company issued an announcement on the “Action Plan to Promote the Double Improvement of Quality and Return”. The main measures are: (1) stick to the original intention and focus on the main business; (2) adhere to R&D and innovation to consolidate competitive advantage; (3) improve corporate governance and improve standardized operation
A-share changes丨The concept of ophthalmology medicine bucked the trend and promoted eye medicine to another record high
Glonghui, March 21 | Guangzheng Ophthalmology went up and down in a straight line. Ho's Ophthalmology surged more than 10%, Sinqi Eye Medicine surged 7%, and reached another record high in the intraday period. Sharp Ace and Puri Ophthalmology were ahead of the curve. According to the news, Sinqi Pharmaceutical previously announced on March 11 that it obtained a drug registration certificate for atropine sulphate eye drops. The approved clinical indication is to slow the progression of myopia in children aged 6 to 12 with a spherical degree of -1.00D to -4.00D (astigmatism ≤ 1.50D, refractive error ≤ 1.50D).
Sinqi Pharmaceutical (300573): Low-concentration atropine was successfully approved, and we look forward to its rapid sales volume
Incident: On March 11, 2024, the company issued an announcement. The company's atropine sulfate eye drops met the relevant requirements for drug registration and obtained a drug registration certificate. The major variety of low concentration atropine was successfully approved, and we look forward to its rapid sales volume:
Changes in Hong Kong stocks | Okanvision Bio-B (01477) is now up more than 7% Sinqi Eye Medication Atropine Eye Drops Approved Clinical Trials of Listed Companies' Products Previously Approved
Okanvision Bio-B (01477) is now up more than 7%. As of press release, it is up 7.57% to HK$5.97, with a turnover of HK$10.8087 million.
A-share changes | Sinqi Pharmaceutical rose more than 6% to a record high and obtained a registration certificate for atropine sulphate eye drops
Gelonghui, March 12 | Sinqi Pharmaceutical (300573.SZ), which surged 12.88% yesterday, once again increased by more than 6%, reaching a new high market price of 199.99 yuan, with a total market value of 24.4 billion yuan. The company announced yesterday after the market that it has received the “Drug Registration Certificate” for atropine sulfate eye drops approved and issued by the State Drug Administration. Recently, the company issued an announcement on the “Double Improvement of Quality and Return” action plan. It will continue to increase investment in R&D and improve product layout in various fields of ophthalmology.
Express News | Sinqi Pharmaceutical: Obtained a registration certificate for atropine sulphate eye drops
Express News | Sinqi Pharmaceutical: Will continue to increase investment in R&D and improve product layout in various fields of ophthalmology
Sinqi Pharmaceutical (300573.SZ): Currently, the company has no drugs to treat pediatric astigmatism
Gelonghui, Feb. 27丨Sinqi Pharmaceutical (300573.SZ) said on the investor interactive platform that currently the company has no drugs to treat astigmatism in children. In the future, the company will continue to enrich its product pipeline to meet the pharmaceutical needs of the ophthalmology market.
Analysis
Price Target
No Data
